A study published May 2 in the journal Cancer suggests how both existing and emerging immunotherapy treatments could be successful for sarcomas. Two sarcoma subtypes — leiomyosarcoma and pleomorphic — showed biological characteristics suggesting they are susceptible to an existing immunotherapy approach known as checkpoint inhibitors. This treatment works by blocking a protein that keeps immune cells from attacking cancerous cells.
Soon after he was diagnosed with a dedifferentiated liposarcoma, C. Norman Coleman reached out to The Cancer Letter and the Cancer History Project to initiate a series of interviews about his life and career.
